Provided by Tiger Fintech (Singapore) Pte. Ltd.

Allogene Therapeutics Inc.

1.18
-0.0200-1.67%
Post-market: 1.17-0.0099-0.84%19:58 EDT
Volume:5.18M
Turnover:6.13M
Market Cap:258.10M
PE:-0.97
High:1.23
Open:1.20
Low:1.17
Close:1.20
Loading ...

Allogene Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
24 Jun

Bernstein Reaffirms Their Hold Rating on Allogene Therapeutics (ALLO)

TIPRANKS
·
20 Jun

Deborah M. Messemer, Director, Reports Disposal of Allogene Therapeutics Inc. Common Shares

Reuters
·
13 Jun

Analysts’ Opinions Are Mixed on These Healthcare Stocks: GlaxoSmithKline (GB:GSK), Sartorius Stedim Biotech (GB:0RG8) and Allogene Therapeutics (ALLO)

TIPRANKS
·
11 Jun

Allogene Therapeutics (ALLO) Receives a Hold from Bernstein

TIPRANKS
·
06 Jun

Canaccord Genuity Reaffirms Their Buy Rating on Allogene Therapeutics (ALLO)

TIPRANKS
·
02 Jun

Allogene Therapeutics (ALLO) Receives a Buy from Piper Sandler

TIPRANKS
·
02 Jun

BRIEF-Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses With Allo-316 In Heavily Pretreated Advanced Renal Cell Carcinoma At ASCO

Reuters
·
01 Jun

Allogene Therapeutics Inc - Single Dose of Allo-316 Achieves 31% Response Rate

THOMSON REUTERS
·
01 Jun

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses With Allo-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at Asco

THOMSON REUTERS
·
01 Jun

Allogene Therapeutics Inc. to Participate in Goldman Sachs Annual Global Healthcare Conference

Reuters
·
23 May

Allogene Therapeutics Unveils Promising Results for ALLO-316 in Kidney Cancer and Cema-Cel in Lymphoma at ASCO 2025

Reuters
·
23 May

Binance Wallet's new TGE ALLO (RWA) concludes oversubscribed by over 143 times

Blockbeats
·
22 May

Binance Wallet's new TGE ALLO (RWA) is now open for investment

Blockbeats
·
22 May

Binance Alpha ALLO (RWA) TGE Threshold is 195 points

Blockbeats
·
22 May

Binance Wallet will list the ALLO TGE

Blockbeats
·
21 May

Allogene Therapeutics Inc : Citigroup Cuts Target Price to $4 From $8

THOMSON REUTERS
·
15 May

Allogene Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
15 May

Allogene Therapeutics Price Target Maintained With a $10.00/Share by RBC Capital

Dow Jones
·
14 May

Piper Sandler Sticks to Its Buy Rating for Allogene Therapeutics (ALLO)

TIPRANKS
·
14 May